Eris Lifesciences Ltd · NSE:ERIS

Eris Lifesciences — Q2 FY19 Earnings Presentation

10 slides from Eris Lifesciences's earnings presentation, Nov 3, 2018

  1. Slide 1: Investor presentation filing letter to exchanges

    Date: 3rd November, 2018 To To The Department of Corporate Services National Stock Exchange of India Limited BSE Limited Exchange Plaza Phiroze Jeejeebhoy Towers Bandra Kurla Complex Dalal Street Bandra (E) Mumbai- 400001 Mumbai-400051 Security Code: 540596 Symbol: ERIS SUBJECT: INVESTOR PRESENTATIO

  2. Slide 2: Q2 19 Investor Presentation

    Eris Q2 19 Investor Presentation

  3. Slide 3: Safe Harbor Statement

    Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and the underlying assumptions

  4. Slide 4: Patient Engagement Initiatives

    PATIENT ENGAGEMENT INITIATIVES IMPROVING HEALTH OUTCOMES PATIENT ENGAGEMENT – the core of our business model. The aim is to improve health outcomes and the doctor – patient relationship with detailed data Identifying gaps in the healthcare delivery ecosystem and addressing those gaps with unique pat

  5. Slide 5: India Heart Study

    INDIA HEART STUDY To generate the first biggest epidemiological data in the country on Office and Home Blood Pressure Measurement

  6. Slide 6: Results Financial Performance: Q2 FY19

    RESULTS FINANCIAL PERFORMANCE: Q2 FY 19 INR millions Q1 FY 19 Q2 FY 19 qoq GR Q2 FY 18 Q2 19 yoy GR H1 19 yoy GR Sale of Products 2,471 2,606 5% 2,307 13% 23% Other Operating Income 37 36 -2% 186 -80% -68% Revenue from Operations 2,508 2,642 5% 2,492 6% 19% Gross Profit 2,119 2,236 6% 2,093 7% 19% G

  7. Slide 7: Results Financial Performance: Q2 FY19

    RESULTS FINANCIAL PERFORMANCE: Q2 FY 19 INR millions Q1 FY 19 Q2 FY 19 qoq GR Q2 FY 18 Q2 19 yoy GR H1 19 yoy GR EBITDA 886 1,007 14% 978 3% 12% EBITDA margin 35% 38% 39% Depreciation and Amortisation 1 73 83 14% 53 57% 57% EBIT 813 924 14% 925 0% 9% EBIT margin 32% 35% 37% Finance cost 2 71 63 -12%

  8. Slide 8: FY19 - Growth Trend and Productivity

    FY 19 - Growth Trend and Productivity Modest yoy growth on high base of Q2 18 ERIS Quarterly Sales INR MN 3,000 2,642 2,491 2,508 2,500 2,090 2,122 2,000 1,500 1,000 500 - Q2 18 Q3 18 Q4 18 Q1 19 Q2 19 IPM Rank and Productivity IPM Rank * MRs YPM Lacs per month 24 1,937 4.5 Source: Internal numbers

  9. Slide 9: FY19 - Growth Trend across Categories

    FY 19 – Growth Trend across Categories Growth Rate Category % of Total Revenue Q1 19 to Q2 19 Chronic ERIS 62% 5% IPM 31% 2% Sub Chronic ERIS 23% 2% IPM 21% 4% Acute ERIS 15% -4% IPM 48% 11% Source: AIOCD AWACS

  10. Slide 10: Thank You

    Eris THANK YOU

Eris Lifesciences — Q2 FY19 Earnings Presentation on 6ix